.png)
Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Is the tirzepatide delivered in the only proven effective method
Disease Indications Diabetes Manufacturer Usage Subcutaneous Medicine approved by European Medical Agency (EMA) Food and Drug Administration (FDA) Pharmaceuticals and Medical Devices Agency (PMDA) Why trust us
SURMOUNT-1 Trial (New England Journal of Medicine, 2022) Randomized, double-blind, placebo-controlled 2,539 participants 72 weeks NCT04184622 Tirzepatide 5 mg -16.0% Mean body weight reduction Tirzepatide 10 mg -21.4% Mean body weight reduction Tirzepatide 15 mg -22.5% Mean body weight reduction Placebo group: -2.4% All results statistically significant (p 27 with Comorbidities Overweight or obese patients (Indian cutoff BMI 23+ with risk factors) seeking significant, sustained weight loss
**Patients without diabetes and with BMI 30, or BMI 27 plus a weight-related condition, lost an average of 20% of their body weight by 1 year in a 72-week trial studying the highest maintenance dose of Zepbound (15 mg), when paired with diet and exercise changes (compared to 3% with diet and exercise alone)
US$ 29.00
US$ 26.79
US$ 23.59
